International Stem Cell Corporation (ISCO)
| Market Cap | 7.01M |
| Revenue (ttm) | 8.49M |
| Net Income (ttm) | -4.72M |
| Shares Out | 7.54M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $0.9299 |
| Previous Close | $0.9600 |
| Change ($) | -0.0301 |
| Change (%) | -3.14% |
| Day's Open | 0.8899 |
| Day's Range | 0.8899 - 0.9299 |
| Day's Volume | 575 |
| 52-Week Range | 0.3 - 1.08 |
News
There are no news available yet.
About ISCO
International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare... [Read more...]
| Industry Biotechnology | Founded 2001 |
| CEO Dr. Andrey Semechkin | Employees 39 |
| Stock Exchange OTCMKTS | Ticker Symbol ISCO |
Financial Performance
In 2019, ISCO's revenue was $9.47 million, a decrease of -14.58% compared to the previous year's $11.09 million. Losses were -$4.27 million, 100.1% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for ISCO is 0.54, which is a decrease of -41.93% from the latest price.